FDA has granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing-based test that simultaneously screens tumor samples for biomarkers associated with three FDA-approved therapies for non-small cell lung cancer.
Read MoreA number of oncology centers have developed and implemented liquid biopsy tests not only for lung cancer, but for breast, colorectal, gynecologic, ovarian, prostate, and skin cancers as well.
Read More
Blood-based genomic tests are improving treatment decision and start times.
Read More
Protecting sample stability ensures the utility of the latest generation of TB tests.
Read More
This month’s issue features emerging technologies from such companies as Clinical Genomics, Hamilton Storage, and Symcel.
Read More